[CD30 (Ki-1+) anaplastic large cell lymphomas].
Bagot
M
M
Service de Dermatologie, Hôpital Henri-Mondor, Créteil.
Wechsler
J
J
Cosnes
A
A
Haioun
C
C
Divine
M
M
Gaulard
P
P
Henni
T
T
Revuz
J
J
D000328:Adult; D000943:Antigens, Differentiation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D014750:Vincristine / Q000008:administration & dosage
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide
Lymphomes à grandes cellules anaplasiques CD30 (Ki-1)+.